Gyre Therapeutics, Inc. (GYRE)
6.71
+0.02
(+0.30%)
USD |
NASDAQ |
Sep 16, 13:24
Gyre Therapeutics Profit Margin (Quarterly) : -49.03% for June 30, 2026
Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -49.03% |
| March 31, 2026 | -43.78% |
| December 31, 2025 | -3.67% |
| September 30, 2025 | 19.42% |
| June 30, 2025 | -7.52% |
| March 31, 2025 | 16.93% |
| December 31, 2024 | 2.04% |
| September 30, 2024 | 11.21% |
| June 30, 2024 | 17.99% |
| March 31, 2024 | 36.56% |
| December 31, 2023 | -72.01% |
| September 30, 2023 | 23.44% |
| June 30, 2023 | 12.85% |
| March 31, 2023 | 16.91% |
| December 31, 2022 | |
| September 30, 2022 | |
| June 30, 2022 | |
| March 31, 2022 | -1.83K% |
| December 31, 2021 | -833.2% |
| September 30, 2021 | -1.10K% |
| June 30, 2021 | -1.76K% |
| March 31, 2021 | -1.53K% |
| December 31, 2020 | -930.9% |
| September 30, 2020 | -1.80K% |
| June 30, 2020 | -1.04K% |
| Date | Value |
|---|---|
| March 31, 2020 | -24.76% |
| December 31, 2019 | |
| September 30, 2019 | |
| June 30, 2019 | |
| March 31, 2019 | |
| December 31, 2018 | |
| September 30, 2018 | |
| June 30, 2018 | |
| March 31, 2018 | -84.03K% |
| December 31, 2017 | -1.81K% |
| September 30, 2017 | -1.82K% |
| June 30, 2017 | -5.29K% |
| March 31, 2017 | -1.53K% |
| December 31, 2016 | -5.28K% |
| September 30, 2016 | -4.38K% |
| June 30, 2016 | -4.43K% |
| March 31, 2016 | -3.30K% |
| December 31, 2015 | -4.71K% |
| September 30, 2015 | -4.63K% |
| June 30, 2015 | -200.7% |
| March 31, 2015 | -425.3% |
| December 31, 2014 | -193.8% |
| September 30, 2014 | -274.6% |
| June 30, 2014 | -22.60K% |
| March 31, 2014 | -17.24K% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Profit Margin (Quarterly) Benchmarks
| Cytokinetics, Inc. | -694.4% |
| ACADIA Pharmaceuticals, Inc. | 10.23% |
| Alnylam Pharmaceuticals, Inc. | 12.74% |
| Anika Therapeutics, Inc. | 10.15% |
| Savara, Inc. | -- |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | -13.75% |
| Return on Assets | -11.65% |
| Return on Invested Capital | -13.60% |
| Gross Profit Margin (Quarterly) | 92.41% |
| Operating Margin (Quarterly) | -47.62% |
| Return on Net Operating Assets | -27.26% |